Oxford Biomedica plc

OXBDF·OTC Markets OTCPK·Healthcare

FollowCompareShare

6.92+0.22 (+3.28%)today

At close: Oct 16, 4:00 PM EDT · May be delayed up to 15 min · USD

1D5D1M6MYTD1Y5Y10Y20YAll

MountainLineCandles

Indicators

Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.

Key statistics

Previous close6.70

Open6.70

Day range6.706.92

52-week range5.8012.61

Off day high0.00%

Off 52-week high−45.12%

Volume7.46K

Avg. volume (3M)1.06K

Market cap837.69M

EPS (TTM)-0.4300

Forward P/E—

P/E ratio (TTM)—

Dividend yield—

Beta (5Y)1.11

Shares outstanding121.05M

Short interest—

Earnings dateSep 22, 2026

Analyst target—

Profit margin−23.23%

Related companies

Compare ›

Also watched

What visitors to Oxford Biomedica's page also look at.

Company	Mkt cap	Price	Today
PHMMPHARMA MAR SAPHMMF	1.63B	94.60	0.00%
PHGUPharming Group NVPHGUF	675.93M	0.9550	+2.80%
PTCHPureTech Health PLCPTCHF	362.87M	1.4800	0.00%
INRLValneva SEINRLF	639.11M	3.3700	0.00%
CUVLClinuvel Pharmaceuticals LimiteCUVL	264.55M	5.24	+0.10%

From the 4Search instruments index: what each company does (its business description), its industry, size, headquarters and the markets it serves; and from a year of daily prices, which move together. Prices may be delayed up to 15 min.

Latest news

All OXBDF news ›

TradingView·3d agoPositive

REG - Oxford Biomedica PLC - Appointment of Independent Non-Executive Director

Oxford, UK – 16 October 2026: OXB OXB, a global quality and innovation-led cell and gene therapy CDMO, today announces the appointment of Dr Joachim Kreuzburg as an Independent Non-Executive Director, effective on 23 November 2026. Save as…

MarketScreener·6d agoNegative

Whitbread raised; Segro, Oxford BioMedica cut

Published on 08/18/2026 at 04:39 am EDT Bernstein raises Whitbread to 'market-perform' (underperform) - price target 2,400 (2,100) pence Berenberg cuts Segro to 'hold' (buy) - price target 991 (995) pence DZ Bank raises fair value for…

@kalkineuk·Oct 12

Is Oxford Biomedica (LSE:OXB) Gaining Attention As Its Vector Platform Broadens In October?

It is one of the more specialised names on the London market, and its fortunes depend heavily on the progress of its clients' therapies through the clinic. The group built its name on LentiVector technology, and is now pushing its InAAVate…

@kalkineuk·Oct 11Positive

Oxford Biomedica (LSE:OXB) Revenue Growth and Firm Guidance Support Recovery While FTSE 100 Trades Higher

Oxford Biomedica, a cell and gene therapy contract development and manufacturing organisation, reported growth in first-half revenue and maintained its full-year guidance. Manufacturing revenue rose on higher batch volumes, and a new…

@kalkineuk·Oct 7

Outside the FTSE 100, what does the latest incentive award say about Oxford Biomedica (LSE:OXB) as it builds its cell and gene therapy services?

Under the scheme described, performance is measured mainly through revenue and operating profitability, with revenue given the heavier weighting and margin the remainder, all assessed on a constant currency basis. Remuneration structures…

From articles in the 4Search news index.

In the news

14mentions in 30 days

14with it in the headline

Positivesentiment

Mentioned with

Astrazeneca9Eli Lilly8Novartis8Bristol Myers Squibb7Rolls-Royce7Jefferies6Novo Nordisk5Oxford4

People in the coverage

Harvey Jones8Ben Mcpoland7Christopher Ruane7Mark Hartley Mark Hartley7Mrigank Dhaniwala6Edward Sheldon5

Themes

Pharma7Biotech6Biopharma5Biotechnology5Healthcare5Life Sciences4Type-Newspost4All News and Stock Ideas3

Most coverage from

1. kalkinemedia.com5
2. tradingview.com3
3. marketscreener.com2
4. asktraders.com1
5. businesscloud.co.uk1

Finance and business coverage in the 4Search news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 14 articles, not a forecast.

Market data is provided for information only and comes from free public sources. Prices may be delayed up to 15 minutes; data may be incomplete or inaccurate. Nothing on this page is investment advice or a recommendation to buy or sell any security. News and coverage analytics are drawn from the 4Search index. Terms of use.